Clinical efficacy of high dose treatment with teicoplanin (TEIC) against MRSA infections and trough concentration of TEIC

Japanese Journal of Chemotherapy

Volumn 55, Issue 1, 2007, Pages 8-16

  Ueda, Yasuharu ^a   Noguchi, Shusaku ^a   Maki, Masahiko ^a   Kamisasa, Hiroshi ^a   Mochizuki, Toru ^a   Unemoto, Kyoko ^a   Kurokawa, Akira ^a  

^a NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

Author keywords

High dose administration; MRSA; Pharmacokinetics; Severe infection; Teicoplanin

Indexed keywords

CIPROFLOXACIN; FLUMOXIL; METICILLIN; PIPERACILLIN; TEICOPLANIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EMERGENCY CARE; ERADICATION THERAPY; FEMALE; HUMAN; INTENSIVE CARE; LABORATORY TEST; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; NONHUMAN; PNEUMONIA; PSEUDOMONAS AERUGINOSA; SEPTICEMIA; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; WOUND INFECTION;

EID: 33846827253     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Japanese source. 2003; 51:490-6
2. Neu H C, Labthavikul P: In vitro activity of teichomycin compared with those of other antibiotics. Antimicrob Agents Chemother 1983; 24: 425-8
3. Pallanza R, Berti M, Goldstein B P, Mapelli E, Randisi E, Scotti R, et al: Teicoplanin: in vitro and in vivo evaluation in comparison with other antibiotics. J Antimicrob Chemother 1983; 11: 419-25
4. Greenwood D: Microbiological properties of teicoplanin. J Antimicrob Chemother 1988; 21: 1-13
5. 14C-teicoplanin in healthyvolunteers. J Antimicrob Chemother 1988; 21 (Suppl A): 23-8
6. Japanese source. 1999; 15: 89-95
7. Sahai J: Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome". Antimicrob Agents Chemother 1990; 34: 765-9
8. Poirier T I, Giudici R A: Survey of clinical pharmacokinetic software for microcomputers. Hosp Pharm 1992; 27: 971-7
9. Japanese source. 1989; 44: 2544-53
10. Lewis P, Garaud J J, Parenti F: A multi-centre open clinical trial of teicoplanin in infections caused by Gram-positive bacteria. J Antimicrob Chemother 1988; 21 (Suppl A): 61-7
11. Japanese source. 1993; 41: 32-40
12. Japanese source. 1993; 41: 47-55
13. Jpn J Antibiot 1999; 52: 268-77
14. Japanese source. 1992; 50: 1060-5
15. Jpn J Antibiotics 1994; 47: 771-80
16. Chambers H F, Kennedy S: Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother 1990; 34: 510-4
17. MacGowan A P, McMullin C M, White L O, Reeves D S, Davis E, Speller D C E, et al: Serum monitoring of teicoplanin. J Antimicrob Chemother 1992; 30: 399-402
18. Livornese L L, Gold M C C, Johnson C C, Measley R, Kaye D, Korzeniowski O, et al: Clinical evaluation of teicoplanin in the treatment of Gram-positive bacterial intravascular infections. J Antimicrob Chemother 1993; 31: 188-91
19. Fauser A A, Lang E, Dolken G, Bross K J, Schmid J, Sorgel F: Treatment of severe sepsis in bone marrow transplant recipients with teicoplanin in combination with β-lactams and aminoglycosides. Infection 1991; 19: 195-200
20. Van der Auwera P, Aoun M, Meunier F: Randomised study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother 1991; 35: 451-7
21. Charbonneau P, Harding I, Garaud J J, Aubertin J, Brunet F, Doart Y: Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for gram-positive infections in intensive care patients. Int Care Med 1994; 20: S35-42
22. Gilbert D N, Wood C A, Kimbrough R C, and The Infectious Disease Consortium of Oregon: Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravasculara infection. The infectious disease consortium of Oregon. Antimicrob Agents Chemother 1991; 35: 79-87
23. Brunet F, Vedel G, Dreyfus F, Vaxelaire J F, Giraud T, Schremmer B, et al; Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur J Clin Microbiol Infet Dis 1990; 9: 145-7
24. Lesne-Hulin A, Bourget P, Le Bever H, Ainaud P, Carsin H: Therapeutic monitoring of teicoplanin in a severely burned patient. Ann Fr Anesth Reanim 1997; 16: 374-7
25. Venditti M, Gelfusa V, Serra P, Brandimarte C, Micizzi A, Martino P: 4-week treatment of streptococcal native valve endocarditis with high-dose teicoplanin. Antimicrob Agents Chemother 1992; 36: 723-6
26. Pea F, Viale P, Candoni A, Pavan F, Pagani L, Damiani D, et al: Teicoplanin in patients with acute leukaemia and febrile neutropenia:a special population benefiting from higher dosages. Clin Pharmacokinet 2004; 43: 405-15